LianBio

    LianBio

    NNASDAQ:LIAN
    0.42
    USD
    +0.00
    (-0.89%)
    2019 Y
    2020 Y
    2021 Y
    2022 Y
    TTM
    Revenue per Share
    - -
    - -
    - -
    - -
    - -
    Basic EPS, GAAP
    - -
    -1.33
    -5.71
    -1.02
    -0.82
    Free Cash Flow per Basic Share
    - -
    -0.94
    -4.79
    -0.94
    -0.78
    Dividend per Share
    - -
    - -
    - -
    - -
    - -
    Book Value per Share
    - -
    -1.56
    -10.47
    -4.36
    -5.03
    Tangible Book Value per Share
    - -
    -0.93
    11.26
    2.72
    2.2
    Basic Weighted Avg Shares
    - -
    105
    34
    108
    107
    Sales/Revenue/Turnover
    - -
    - -
    - -
    - -
    - -
    Operating Margin (%)
    - -
    - -
    - -
    - -
    - -
    Depreciation Expense
    - -
    - -
    1
    1
    1
    Net Income, GAAP
    - -
    -140
    -196
    -110
    -88
    Effective Tax Rate (%)
    - -
    - -
    - -
    - -
    - -
    Profit Margin (%)
    - -
    - -
    - -
    - -
    - -
    Working Capital
    40
    271
    385
    289
    232
    LT Debt
    - -
    1
    4
    2
    1
    Total Equity
    -15
    -98
    387
    294
    236
    Return on Invested Capital (%)
    - -
    - -
    - -
    - -
    - -
    Return on Capital (%)
    - -
    - -
    - -
    - -
    - -
    Return on Common Equity (%)
    - -
    - -
    - -
    - -
    - -

    Capital Structure

    USD

    •

    in mil. unless spec.
    Mar'23
    Jun'23
    Sep'23
    ST Debt
    2
    2
    2
    LT Borrowings
    - -
    - -
    - -
    LT Finance Leases
    2
    1
    1
    Preferred Equity and Hybrid Capital
    - -
    - -
    - -
    Shares Outstanding
    107
    107
    107
    Market Capitalization
    211
    246
    160

    Working Capital

    USD

    •

    in mil. unless spec.
    Mar'23
    Jun'23
    Sep'23
    Total Current Assets
    296
    273
    258
    Cash, Cash Equivalents & STI
    287
    267
    252
    Accounts Receivable, Net
    - -
    - -
    - -
    Inventories
    - -
    - -
    - -
    Total Current Liabilities
    26
    22
    26
    Payables & Accruals
    20
    15
    17
    ST Debt
    2
    2
    2
    Deferred Revenue
    - -
    - -
    - -

    Growth Rates

    USD

    •

    in mil. unless spec.

    (avg. rate of change)

    10 years
    5 years
    1 year
    Total Equity
    - -
    - -
    -24.19%
    Free Cash Flow
    - -
    - -
    -38.73%
    Net Income, GAAP
    - -
    - -
    -43.82%
    Sales/Revenue/Turnover
    - -
    - -
    - -
    Total Cash Common Dividend
    - -
    - -
    - -

    Quarterly Revenue

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2021
    - -
    - -
    - -
    - -
    - -
    2022
    - -
    - -
    - -
    - -
    - -
    2023
    - -
    - -
    - -
    - -
    - -

    Quarterly Earnings Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2021
    -0.58
    -0.95
    -0.12
    -0.28
    -5.71
    2022
    -0.26
    -0.39
    -0.2
    -0.17
    -1.02
    2023
    -0.22
    -0.2
    -0.22
    - -
    - -

    Quarterly Dividends Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2021
    - -
    - -
    - -
    - -
    - -
    2022
    - -
    - -
    - -
    - -
    - -
    2023
    - -
    - -
    - -
    - -
    - -

    Company Description

    Company Profile APIChatGPT
    Address
    Similar Companies
    Business

    Company News

    Company News APIChatGPT

    • investorplace.com

      Why Is LianBio (LIAN) Stock Moving Today?

    • globenewswire.com

      LianBio Announces Voluntarily Delisting from Nasdaq

    • globenewswire.com

      LianBio Announces Completion of Strategic Review

    • globenewswire.com

      LianBio Announces Departure of Chief Financial Officer

    • globenewswire.com

      LianBio Announces Departure of Chief Executive Officer

    • globenewswire.com

      LianBio's Board of Directors Unanimously Determines not to Pursue Unsolicited Proposal from Concentra Biosciences

    • globenewswire.com

      LianBio Confirms Receipt of Unsolicited Proposal from Concentra Biosciences

    • globenewswire.com

      LianBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

    • zacks.com

      All You Need to Know About LianBio Sponsored ADR (LIAN) Rating Upgrade to Strong Buy

    • globenewswire.com

      LianBio Announces Topline Results from Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis

    • fool.com

      Why LianBio Stock Is Shooting Through the Roof This Week

    • pennystocks.com

      3 Penny Stocks To Buy For Under $5, Are They Worth It?

    • globenewswire.com

      LianBio Announces Presentation of Data from Phase 2a Study of Infigratinib in Patients with Gastric Cancer at ESMO Congress 2023

    • investorplace.com

      Why Is LianBio (LIAN) Stock Up 130% Today?

    • fool.com

      Why LianBio Stock Is Skyrocketing Today

    • pennystocks.com

      4 Hot Penny Stocks To Watch With Big News This Week

    • globenewswire.com

      LianBio Announces Results from Phase 3 EXPLORER-CN Trial of Mavacamten Presented at the European Society of Cardiology Congress and Simultaneous Publication in JAMA Cardiology

    • globenewswire.com

      LianBio Reports Second Quarter 2023 Financial Results and Provides Corporate Update

    • globenewswire.com

      LianBio Announces First Patient Treated in Phase 1 Trial of SHP2 Inhibitor BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations

    • globenewswire.com

      LianBio Partner Tarsus Pharmaceuticals Announces U.S. FDA Approval of XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the Treatment of Demodex Blepharitis